ASH Comments for the Cell and Gene Therapy Access Model for Sickle Cell Disease
Nov 03
2023
American Society of Hematology. (2023).
ASH Comments for the Cell and Gene Therapy Access Model for Sickle Cell Disease.
Retrieved from https://www.hematology.org/advocacy/policy-news-statements-testimony-and-correspondence/testimony-and-correspondence/ash-comments-for-the-cell-and-gene-therapy-access-model-for-sickle-cell-disease.
American Society of Hematology.
"ASH Comments for the Cell and Gene Therapy Access Model for Sickle Cell Disease." Hematology.org.
https://www.hematology.org/advocacy/policy-news-statements-testimony-and-correspondence/testimony-and-correspondence/ash-comments-for-the-cell-and-gene-therapy-access-model-for-sickle-cell-disease
(label-accessed November 28, 2023).
"American Society of Hematology."
ASH Comments for the Cell and Gene Therapy Access Model for Sickle Cell Disease, 28 Nov. 2023 ,
https://www.hematology.org/advocacy/policy-news-statements-testimony-and-correspondence/testimony-and-correspondence/ash-comments-for-the-cell-and-gene-therapy-access-model-for-sickle-cell-disease.
